Riskpilot← Back to searchSign inGet full accessENDOX ApS
APSActiveCVR 31084733Lyngebækgårds Alle 4Beauty care and other beauty treatment activities · NACE 9622Est. 2007— employees
Revenue 2024
DKK -60K
+92% vs 2023
EBITDA margin
100.0%
-92% vs 2023
Equity ratio
99.7%
Financial strength
Net profit 2024
DKK -124K
-109% vs 2023
| Revenue | DKK -60K | +92% |
| EBITDA | DKK -60K | -92% |
| Net profit | DKK -124K | -109% |
| Total assets | DKK 9,8M | -3% |
| Equity | DKK 9,7M | -1% |
| Employees | — | — |
Legal name
ENDOX ApS
CVR number
31084733
Legal form
Anpartsselskab
NACE code
9622 · Beauty care and other beauty treatment activities
Founded
7. december 2007
Share capital
DKK 141.880
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabet har til formål at yde rådgivning, ud-øve konsulentvirksomhed og drive virksom-hed relateret til forskning, udvikling, produkti-on og kommercialisering af kemiske, biotek-nologiske og medicinske produkter, substan-ser samt medicinske anordninger til behand-ling af neurodegenerative sygdomme, herun-der immaterielle rettigheder knyttet til sådan-ne produkter, substanser og anordninger. Selskabet kan, efter direktionens nærmere skøn, udøve virksomhed indenfor beslægtede områder eller med beslægtet formål.
Address
Lyngebækgårds Alle 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -9 | -14 | -13 | -15 | -33 | -46 | -35 | -35 | -35 | -40 | -40 | -31 | -60 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -9 | -14 | -13 | -15 | -33 | -46 | -35 | -35 | -35 | -40 | -40 | -31 | -60 |
| Depreciation & amort. | -0 | -212 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -9 | -226 | -13 | -15 | -33 | -46 | -35 | -35 | -35 | -40 | -40 | -31 | -60 |
| Net financials | 5 | 5 | 5 | -19 | -57 | -375 | -182 | 127 | 2.277 | -692 | 105 | 1.575 | -55 |
| Profit before tax | -3 | -221 | -8 | -34 | -90 | -421 | -218 | 91 | 2.242 | -733 | 64 | 1.544 | -115 |
| Tax | -0 | -0 | -0 | -58 | -5 | -9 | -72 | -13 | -42 | -0 | -18 | 178 | 9 |
| Net profit | -3 | -221 | -8 | 24 | -85 | -412 | -145 | 104 | 2.284 | -733 | 82 | 1.367 | -124 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 608 | 387 | 379 | 1.863 | 1.808 | 8.599 | 11.913 | 12.608 | 9.156 | 8.428 | 8.518 | 10.067 | 9.760 |
| Equity | 598 | 377 | 369 | 393 | 308 | 6.895 | 6.750 | 6.854 | 9.138 | 8.406 | 8.488 | 9.854 | 9.730 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10 | 10 | 10 | 1.469 | 1.501 | 1.703 | 5.163 | 5.754 | 18 | 23 | 30 | 213 | 30 |
| Total debt | 10 | 10 | 10 | 1.469 | 1.501 | 1.703 | 5.163 | 5.754 | 18 | 23 | 30 | 213 | 30 |
EBITDA margin
-5997600.0%
This company
15.8%
Market median
-37959594% vs market
20122024
Equity ratio
99.7%
This company
38.2%
Market median
+161% vs market
20122024
Return on equity
-1.3%
This company
18.4%
Market median
-107% vs market
20122024
Net profit margin
-12442600.0%
This company
8.1%
Market median
-153612446% vs market
20122024
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20122024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TR Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
JB Management | Management | 2007 | — | — |
MW Management | Management | 2007 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NENSIUS RESEARCH ApS | Company | 100.0% | 100.0% | 2008 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
KAPITALFORMIDLINGS INSTITUTTET A/S
ENDOX ApS Board members of ENDOX ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Torben Rønje | Chief Executive Officer | 0 companies |
| Jan Bjerrum Bach | Management | 0 companies |
| Morten Weidner | Management | 0 companies |